Abstract
Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic.
Objective: New therapeutics against cancer metastasis is to be discovered.
Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients—opposite tumor pathogenesis routes between primary and metastatic tumors.
Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on).
Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever.
Keywords: Neoplasm metastases, cancer chemotherapy, personalized cancer therapy, drug sensitivity testing, drug combination, pharmacogenetics, personalized medicine.
Current Drug Therapy
Title:Cancer Metastasis, a Clinical Dilemma for Therapeutics
Volume: 11 Issue: 2
Author(s): Da-Yong Lu*, Ting-Ren Lu, Bin Xu, Rong-Xin Qi, Nagendra S. Yarla, Xiao-Die Zhou and Jian Ding
Affiliation:
- Shanghai University, Shanghai 200444, P.R. China.,China
Keywords: Neoplasm metastases, cancer chemotherapy, personalized cancer therapy, drug sensitivity testing, drug combination, pharmacogenetics, personalized medicine.
Abstract: Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic.
Objective: New therapeutics against cancer metastasis is to be discovered.
Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients—opposite tumor pathogenesis routes between primary and metastatic tumors.
Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on).
Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever.
Export Options
About this article
Cite this article as:
Lu Da-Yong*, Lu Ting-Ren, Xu Bin, Qi Rong-Xin, Yarla S. Nagendra, Zhou Xiao-Die and Ding Jian, Cancer Metastasis, a Clinical Dilemma for Therapeutics, Current Drug Therapy 2016; 11 (2) . https://dx.doi.org/10.2174/1574885511666160810143216
DOI https://dx.doi.org/10.2174/1574885511666160810143216 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Contraception in Women with Medical Conditions
Current Women`s Health Reviews Novel Approaches to Target Pancreatic Cancer
Current Cancer Drug Targets Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy
Mini-Reviews in Medicinal Chemistry Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Amino Acid Derived Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs
Current Topics in Medicinal Chemistry Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma
Current Radiopharmaceuticals Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Current Clinical Pharmacology Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy